Stanford Study Data Supports Reviving MCIT

article image
ARTICLE SUMMARY:

CMS’ and Congress’ reconsideration of the recently-repealed MCIT program may be bolstered by a Stanford Biodesign analysis showing such a policy can improve both patient access and product innovation. Now the program just needs to be re-enacted.

It’s hard to think of a policy program in any area that has experienced more rapid highs and lows than MCIT (Medicare Coverage of Innovative Technology). Nearly a decade in the making, the program was adopted in the latter stages of the previous administration which for many was unexpected given that White House’s general stance against additional government regulations, only to be repealed on November 12, 2021, by the current administration. With MCIT under reconsideration by both CMS and Congress, a recent study by a newly-launched policy initiative within the Stanford Biodesign program may help support this revival effort, as it shows that such an approach can help improve both patient access and product innovation.

×



This article is restricted to subscribers only.

Sign in to continue reading.

Questions?

We're here to help! Please contact us at: